nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Antifungal drug susceptibility testing and resistance in Aspergillus
|
Warnock, David W. |
|
1999 |
|
5 |
p. 326-334 9 p. |
artikel |
2 |
Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype
|
Henderson, Clare |
|
2003 |
|
5 |
p. 247-256 10 p. |
artikel |
3 |
Are cytochrome b gene mutations the only cause of atovaquone resistance in Pneumocystis ?
|
Kaneshiro, Edna S. |
|
2001 |
|
5 |
p. 322-329 8 p. |
artikel |
4 |
Atovaquone resistance in malaria parasites
|
Vaidya, Akhil B |
|
2000 |
|
5 |
p. 283-287 5 p. |
artikel |
5 |
Breast cancer response to paclitaxel in vivo
|
Symmans, Fraser W. |
|
2001 |
|
5 |
p. 297-302 6 p. |
artikel |
6 |
cDNA Technologies and their application to drug resistance research: power, potential and problems
|
Duan, Zhenfeng |
|
2000 |
|
5 |
p. 277-282 6 p. |
artikel |
7 |
Cellular survival pathways and resistance to cancer therapy
|
Dennis, Phillip A. |
|
1998 |
|
5 |
p. 301-309 9 p. |
artikel |
8 |
Cell wall targets in methicillin-resistant staphylococci
|
Labischinski, Harald |
|
1999 |
|
5 |
p. 319-325 7 p. |
artikel |
9 |
Clinical cancer research 2002: new agents and therapies
|
Gietema, J.A |
|
2002 |
|
5 |
p. 192-203 12 p. |
artikel |
10 |
Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far
|
Kontoyiannis, Dimitrios P. |
|
2003 |
|
5 |
p. 257-269 13 p. |
artikel |
11 |
Drug resistance in ovarian cancer: The emerging importance of gene transcription and spatio-temporal regulation of resistance
|
Richardson, Alan |
|
2005 |
|
5 |
p. 311-321 11 p. |
artikel |
12 |
Drug transport and drug resistance in African trypanosomes
|
Mäser, Pascal |
|
2003 |
|
5 |
p. 281-290 10 p. |
artikel |
13 |
Editorial Board
|
|
|
2002 |
|
5 |
p. i- 1 p. |
artikel |
14 |
Editorial Board
|
|
|
2003 |
|
5 |
p. i- 1 p. |
artikel |
15 |
Editorial Board
|
|
|
2005 |
|
5 |
p. i- 1 p. |
artikel |
16 |
Erratum
|
Stöhr, Klaus |
|
2000 |
|
5 |
p. 313- 1 p. |
artikel |
17 |
Erratum to “Strategies to target HER2/neu overexpression for cancer therapy”
|
Chen, Jin-Shing |
|
2003 |
|
5 |
p. 295-296 2 p. |
artikel |
18 |
If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells
|
Roninson, Igor B. |
|
2001 |
|
5 |
p. 303-313 11 p. |
artikel |
19 |
Infectious disease 2000: drug resistance and new drugs
|
Georgopapadakou, Nafsika H. |
|
2000 |
|
5 |
p. 265-269 5 p. |
artikel |
20 |
Infectious disease 2001: drug resistance, new drugs
|
Georgopapadakou, Nafsika H |
|
2002 |
|
5 |
p. 181-191 11 p. |
artikel |
21 |
Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives
|
Dermond, Olivier |
|
2001 |
|
5 |
p. 314-321 8 p. |
artikel |
22 |
Insights into oxazaphosphorine resistance and possible approaches to its circumvention
|
Zhang, Jing |
|
2005 |
|
5 |
p. 271-297 27 p. |
artikel |
23 |
Is there a role for glyoxalase I inhibitors as antitumor drugs?
|
Tew, Kenneth D. |
|
2000 |
|
5 |
p. 263-264 2 p. |
artikel |
24 |
Liposome-based approaches to overcome anticancer drug resistance
|
Mamot, Christoph |
|
2003 |
|
5 |
p. 271-279 9 p. |
artikel |
25 |
Literature highlights:Recent research in infectious disease drug resistance(6/5)
|
|
|
2003 |
|
5 |
p. 291-293 3 p. |
artikel |
26 |
Literature highlights: recent research in infectious disease drug resistance
|
|
|
2005 |
|
5 |
p. 331-338 8 p. |
artikel |
27 |
MEETINGS CALENDAR
|
|
|
2001 |
|
5 |
p. 331-333 3 p. |
artikel |
28 |
Meetings calendar
|
|
|
1998 |
|
5 |
p. 343-344 2 p. |
artikel |
29 |
Meetings Calendar
|
|
|
1999 |
|
5 |
p. 341-344 4 p. |
artikel |
30 |
Meetings Calendar
|
|
|
2000 |
|
5 |
p. 315-317 3 p. |
artikel |
31 |
Mismatch repair and drug responses in cancer
|
Sedwick, W.David |
|
1999 |
|
5 |
p. 295-306 12 p. |
artikel |
32 |
Molecular basis of metronidazole resistance in pathogenic bacteria and protozoa
|
Land, Kirkwood M. |
|
1999 |
|
5 |
p. 289-294 6 p. |
artikel |
33 |
New physiological functions for drug-transporting P-glycoproteins?
|
Borst, P. |
|
1998 |
|
5 |
p. 337-339 3 p. |
artikel |
34 |
Nucleoside transport and its significance for anticancer drug resistance
|
Mackey, John R. |
|
1998 |
|
5 |
p. 310-324 15 p. |
artikel |
35 |
Origins of the aminoglycoside modifying enzymes
|
Rather, Philip N. |
|
1998 |
|
5 |
p. 285-291 7 p. |
artikel |
36 |
p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53
|
Fojo, Tito |
|
2002 |
|
5 |
p. 209-216 8 p. |
artikel |
37 |
Potential drug targets in cyst-wall biosynthesis by intestinal protozoa
|
Jarroll, Edward L. |
|
2003 |
|
5 |
p. 239-246 8 p. |
artikel |
38 |
Redox-sensitive signaling factors as a novel molecular targets for cancer therapy
|
Pennington, J. Daniel |
|
2005 |
|
5 |
p. 322-330 9 p. |
artikel |
39 |
Resistance to epidermal growth factor receptor-targeted therapy
|
Morgillo, Floriana |
|
2005 |
|
5 |
p. 298-310 13 p. |
artikel |
40 |
Resistance to imatinib (Glivec): update on clinical mechanisms
|
Weisberg, Ellen |
|
2003 |
|
5 |
p. 231-238 8 p. |
artikel |
41 |
Role of fem factors in methicillin resistance
|
Berger-Bächi, Brigitte |
|
1998 |
|
5 |
p. 325-335 11 p. |
artikel |
42 |
Small cell and its stroma: determinant of pan-resistance?
|
Sehested, Maxwell |
|
1999 |
|
5 |
p. 281-283 3 p. |
artikel |
43 |
The impact of antibiotic use on resistance development and persistence
|
Barbosa, Teresa M. |
|
2000 |
|
5 |
p. 303-311 9 p. |
artikel |
44 |
The (patho)physiological functions of the MRP family
|
Renes, Johan |
|
2000 |
|
5 |
p. 289-302 14 p. |
artikel |
45 |
The question begs — what is the role of P-glycoprotein in normal physiology?
|
Johnstone, Ricky W. |
|
1998 |
|
5 |
p. 340-342 3 p. |
artikel |
46 |
The role of caspase-8 in resistance to cancer chemotherapy
|
Kim, Peter K.M. |
|
2001 |
|
5 |
p. 293-296 4 p. |
artikel |
47 |
The tumor microenvironment as a determinant of drug response and resistance
|
Dalton, William S. |
|
1999 |
|
5 |
p. 285-288 4 p. |
artikel |
48 |
39thInterscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) San Francisco, USA, 26–29 September 1999
|
Georgopapadakou, Nafsika H. |
|
1999 |
|
5 |
p. 335-340 6 p. |
artikel |
49 |
Topoisomerase I inhibitors: selectivity and cellular resistance
|
Pommier, Yves |
|
1999 |
|
5 |
p. 307-318 12 p. |
artikel |
50 |
Tumor necrosis factor: clinical use and mechanisms of action
|
Rüegg, Curzio |
|
2000 |
|
5 |
p. 271-276 6 p. |
artikel |
51 |
Tumor senescence as a determinant of drug response in vivo
|
Roninson, Igor B |
|
2002 |
|
5 |
p. 204-208 5 p. |
artikel |
52 |
Virological and clinical implications of resistance to HIV-1 protease inhibitors
|
Condra, Jon H. |
|
1998 |
|
5 |
p. 292-299 8 p. |
artikel |
53 |
Virus-mediated killing of cells that lack p53 activity
|
Nemunaitis, John |
|
2001 |
|
5 |
p. 289-291 3 p. |
artikel |